NCT07219576View on ClinicalTrials.gov

Retifanlimab and Ruxolitinib In Solid Malignancies

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions

Non Small Cell Lung CarcinomaRenal Cell Carcinoma

Interventions

DRUG

Ruxolitinib

Janus kinase 1/2 inhibitor

DRUG

Retifanlimab

Programmed cell death protein-1 blocker

Trial Locations (1)

92093

University of California, San Diego Moores Cancer Center, La Jolla

Sponsors

Collaborators (1)

Incyte Corporation

All Listed Sponsors

collaborator

Incyte Corporation

INDUSTRY

lead

University of California, San Diego

OTHER

NCT07219576 - Retifanlimab and Ruxolitinib In Solid Malignancies | Biotech Hunter | Biotech Hunter